Since IB-R following chronic exposure to ibrutinib resulted in low FOXO3a and PTEN levels and activation of AKT, we examined the effect of acute ibrutinib treatment on this pathway in ibrutinib sensitive CLL and ABC-DLBCL cell lines. Here, AKT1 is linked to B-cell chronic lymphocytic leukemia.